Skip to main content
Premium Trial:

Request an Annual Quote

Mary Taylor New VP Regulatory Affairs at CuraGen; Victor Markowitz to Go From Gene Logic to LBNL; John Keller Appointed to DiaDexus Board; and Others

NEW YORK, Jan.7 (GenomeWeb News) - Mary Taylor has been named as vice president of regulatory affairs at CuraGen, the company said today.

 

Taylor joins the New Haven, Conn., company following a stint as vice president of North American regulatory affairs at Bayer Pharmaceuticals. Prior to joining Bayer, she was at Parke-Davis Pharmaceutical Research Division of Warner-Lambert, now Pfizer Global Research and Development.

 


 

Victor Markowitz told GenomeWeb News Jan. 5 that he is leaving Gene Logic, where he held executive positions for six years, most recently being CIO and senior vice president of data management systems.

 

Markowitz said he is returning to Lawrence Berkeley National Laboratory to head up a new biological data management and technology center. Prior to joining Gene Logic in 1998, he was a staff scientist and project leader in the Data Management Research and Development group at LBNL.

 

In November, Gene Logic announced layoffs of 50 staff in database development and production, and said it would add positions in contract study services, marketing, and sales, as part of a shift in its business strategy.

 


 

John Keller, executive vice president and chief business officer of Incyte, has been appointed to the board of directors of DiaDexus, the company said Jan. 6.

 

DiaDexus, a South San Francisco-based company which is privately held, focuses on development and marketing of diagnostic and therapeutic products using genomics and bioinformatics.

 

Before he took the job at Incyte in September 2003, Keller was vice president of business development at GlaxoSmithKline's worldwide business development group. He was with SmithKline Beecham since 1987.

 


 

J. Donald Payne has been appointed to the board of directors of Boston Biomedica, of West Bridgewater, Mass., the company said Jan. 5.

 

Payne is president and director of Nanospectra Biosciences of Houston, which manufactures medical devices for cancer, opthamology, and diagnostics in the biodefense area. Before joining the company in September 2001, he was senior vice president and CFO of Sensus Drug Development, which was sold to Pharmacia in 2001. He also served as vice president and CFO of LifeCell between 1997 and 1998, and was vice president, finance, and CFO of Aprogenex,a developer and marketer of medical devices that use DNA probes. He also was CFO of private and public entities at UMC Petroleum, and prior to that, worked at Arthur Andersen.

 

 

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.